Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 239

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 239
---
 interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. On April 1, 2024, the Company borrowed an additional $ 0.3million from Prophase (the “Prophase April 2024 Loan”). The loan bears 6% interest per annum and was due on June 1, 2024, which may be extended to the second anniversary upon mutual agreement of the parties. In May 2024, the Company borrowed an additional $ 0.8million from Prophase (the “Prophase May 2024 Loans”). The loans bear 6% interest per annum. Of the aggregate $ 0.8million Prophase May 2024 Loans, $ 0.3million was due on June 1, 2024 and $ 0.5million was due on July 1, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. In July 2024, the Company borrowed an additional $ 83,000from Prophase (the “Prophase July 2024 Loans”). The loans bear 6% interest per annum. Of the aggregate $ 83,000Prophase July 2024 Loans, $ 30,000was due on September 14, 2024, $ 3,000was due on September 24, 2024 and $ 50,000was due on September 29, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. In August 2024, the Company borrowed an additional $ 50,000from Prophase (the “Prophase August 2024 Loans”). The loans bear 6% interest per annum. Of the aggregate $ 50,000Prophase August 2024 Loans, $ 30,000was due on October 12, 2024 and $ 20,000was due on October 13, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. In February of 2025, the Company borrowed an additional $ 0.2million from Prophase (the “Prophase February 2025 Loan”). The Prophase February 2025 Loan bears interest at 6% per annum and is due on April 11, 2025, which may be extended upon mutual agreement of the parties. In March of 2025